Treatment of many haematological diseases is extremely expensive. Apart from providing major subsidization of costs from our own funds (~35% of our total turnover) towards the care of such patients, we also arrange for external funds to further subsidize their care.
Allogeneic Stem Cell Transplantation forThalassemia Major. Hematol Oncol Clin North Am. 2014 Dec;28(6):1187-1200. doi: 10.1016/j.hoc.2014.08.009. Mathews V, Srivastava A, Chandy M. Epub 2014 Sep 22. Review. PubMed PMID: 25459187.